Douglas V. Faller

16.4k citations

277 papers · 13.6k indexed · 2 hit papers · h-index 57

Impact in

Genetics top 0.5%
- Hemoglobinopathies and Related Disorders
Hematology top 0.5%
- Iron Metabolism and Disorders

Papers in

Genetics 54
- Hemoglobinopathies and Related Disorders 36
- Virus-based gene therapy research 19
Hematology 50
- Acute Myeloid Leukemia Research 23

Co-authors: Nancy C. Andrews Susan P. Perrine Stella Kourembanas Steven J. Mentzer Cyrus Vaziri Lora W. Forman Philip A. Marsden Gerald V. Denis
Journals: Blood (31 papers)Journal of Biological Chemistry (23 papers)Journal of Virology (14 papers)Journal of Cellular Physiology (13 papers)Molecular and Cellular Biology (8 papers)
Partner nations: United States Italy Canada

In The Last Decade

Douglas V. Faller

276 papers receiving 13.2k citations

Hit Papers

align trajectories log scale

A rapid micrqpreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells 1991 · 2.2k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1991 Nucleic Acids Research
1991 Journal of Clinical Investigation

Peers

Countries citing papers authored by Douglas V. Faller

Since Specialization

Citations

This map shows the geographic impact of Douglas V. Faller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas V. Faller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas V. Faller more than expected).

Fields of papers citing papers by Douglas V. Faller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas V. Faller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas V. Faller. The network helps show where Douglas V. Faller may publish in the future.

Co-authors

The 25 scholars most cited alongside Douglas V. Faller, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Douglas V. Faller Line = papers co-authored together Douglas V. Faller links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Sky-1214, a Small Molecule Splicing Modulator Targeting FANCL and Fanci, Provides a New Mechanism of Action Targeting Multiple Myeloma and Non-Hodgkin's Lymphoma Blood ·Sebastian Rauch, Stefan O. Reber, Montserrat Pérez-Salvia, Paula Cristina Bessa Matos, Botao Liu, Loren Berry, Olesia Buiakova, Hasane Ratni, Brian Gudenas, Carlo Cusulin, Mostafa Sharaf, Douglas V. Faller, Veronica Costa, Sergey Paushkin	2024	1
2	Epilepsy: Mitochondrial connections to the ‘Sacred’ disease Mitochondrion ·Walter H. Moos, Douglas V. Faller, Ioannis P. Glavas, Jeffrey W. Taliaferro, Krishna Kodukula, Barbara Machado Flores, Donald Yannascoli, Carl A. Pinkert, Whitney R. Powers, Konstantina Sampani, Kosta Steliou, Demetrios G. Vavvas	2023	20
3	Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study Blood Advances ·Bradley M. Haverkos, Önder Alpdoğan, Robert A. Baiocchi, Jonathan E. Brammer, Tatyana Feldman, Marcelo Capra, Elizabeth Brém, Pierre G R St, Phillip Scheinberg, Juliana Pereira, Leyla Shune, Erel Joffe, Patricia A. Young, Susan E. Spruill, Sascha Kaiser, F. Dressler, Ivor Royston, Douglas V. Faller, Doç.dr. Yaşar ÖZKAN, Pierluigi Porcu	2023	25
4	Pathogenic mitochondrial dysfunction and metabolic abnormalities Biochemical Pharmacology ·Walter H. Moos, Douglas V. Faller, Ioannis P. Glavas, David N. Harpp, 贺兰云, Jeffrey W. Taliaferro, Krishna Kodukula, Anastasios Mavrakis, Barbara Machado Flores, Donald Yannascoli, Carl A. Pinkert, Whitney R. Powers, Kosta Steliou, Constantin Tamvakopoulos, Demetrios G. Vavvas, Robert Zamboni, Konstantina Sampani	2021	29
5	A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies Targeted Oncology ·Toshio Shimizu, Yasutoshi Kuboki, Chia‐Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V. Faller, Grant Grove, Neeraj Gupta, Farhad Sedarati, Kyu‐pyo Kim	2021	5
6	Epigenetic treatment of dermatologic disorders Drug Development Research ·Walter H. Moos, Douglas V. Faller, Ioannis P. Glavas, David N. Harpp, Jeffrey W. Taliaferro, Carl A. Pinkert, Whitney R. Powers, Konstantina Sampani, Kosta Steliou, Demetrios G. Vavvas, Krishna Kodukula, Robert Zamboni	2019	2
7	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL) Blood ·Angela Dispenzieri, G R Arunoday, Ashutosh Wechalekar, Stefan Schönland, Kihyun Kım, Vaishali Sanchorawala, Heather Landau, Fiona Kwok, Kenshi Suzuki, Raymond L. Comenzo, Deborah Berg, Guohui Liu, Douglas V. Faller, Giampaolo Merlini	2019	32
8	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML Blood ·Ronan Swords, Steven Coutré, Michael B. Maris, Joshua F. Zeidner, James M. Foran, José C. Cruz, Harry P. Erba, Jesús G. Berdeja, Wayne Tam, Saran Vardhanabhuti, Nitin Chandrashekhar Adgaonkar, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Mutembei Henry M'Ïkiugu, Douglas V. Faller, Michael R. Savona	2018	157
9	Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis Amyloid ·Parameswaran Hari, Huamao Mark Lin, Carl V. Asche, Jinma Ren, Candice Yong, Katarina Luptakova, Douglas V. Faller, Vaishali Sanchorawala	2018	16
10	Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA) Blood ·Jill A. Bell, Aaron Galaznik, Eileen Farrelly, AnnA A. KulAKovA, Augustina Ogbonnaya, Michael Eaddy, Robert J. Fram, Douglas V. Faller, Vamsi Kota	2017	2
11	SIRT1 Inactivation Evokes Antitumor Activities in NSCLC through the Tumor Suppressor p27 Molecular Cancer Research ·Zulkifly Abdullah Mohd, Vinod R. Chougala, Swati Kalgaonkar, Nali Asamoah, Douglas V. Faller, Yan Dai	2014	26
12	Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer Journal of Endocrinology ·Luis Cortez-Salazar, Yan Dai, Douglas V. Faller	2011	62
13	Roles of prohibitin in growth control and tumor suppression in human cancers. PubMed Central ·Sheng Wang, Douglas V. Faller	2008	13
14	RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. PubMed ·Gerald V. Denis, Cyrus Vaziri, Ning Guo, Douglas V. Faller	2000	137
15	Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. PubMed ·Cyrus Vaziri, О Демихова, Douglas V. Faller	1998	91
16	Repression of Platelet-Derived Growth Factor β-Receptor Expression by Mitogenic Growth Factors and Transforming Oncogenes in Murine 3T3 Fibroblasts Molecular and Cellular Biology ·Cyrus Vaziri, Douglas V. Faller	1995	42
17	BALB/c-3T3 Fibroblasts Resistant to Growth Inhibition by Beta Interferon Exhibit Aberrant Platelet-Derived Growth Factor, Epidermal Growth Factor, and Fibroblast Growth Factor Signal Transduction Molecular and Cellular Biology ·Zhao Xin, Douglas V. Faller	1991	3
18	Interferon-γ Modulates Fetal Hemoglobin Synthesis in Sickle Cell Anemia and Thalassemia Journal of Interferon Research ·Barbara A. Miller, Nancy F. Olivieri, sachiko Hirota, Douglas V. Faller, Susan P. Perrine	1990	4
19	Endothelial Cells Synthesize Basic Fibroblast Growth Factor and Transforming Growth Factor Beta Growth Factors ·Robert L. Hannan, Stella Kourembanas, Kathleen C. Flanders, Snezna Rogelj, Anita B. Roberts, Douglas V. Faller, Michael Klagsbrun	1988	99
20	Murine Retroviruses Control Class I Major Histocompatibility Antigen Gene Expression via a trans Effect at the Transcriptional Level Molecular and Cellular Biology ·Gál E, David C. Flyer, Douglas V. Faller	1987	12

About Douglas V. Faller

Douglas V. Faller is a scholar working on Genetics, Hematology, Geriatrics and Gerontology, Oncology and Molecular Biology, having authored 277 papers that have together received 13.6k indexed citations. Recurring topics across this work include Hemoglobinopathies and Related Disorders (36 papers), Acute Myeloid Leukemia Research (23 papers), Protein Degradation and Inhibitors (23 papers), Ubiquitin and proteasome pathways (22 papers), Histone Deacetylase Inhibitors Research (22 papers), Cancer-related Molecular Pathways (21 papers), Epigenetics and DNA Methylation (21 papers) and Virus-based gene therapy research (19 papers). The work is most often cited by research in Genetics (1.8k citations), Hematology (1.7k citations), Cancer Research (1.8k citations), Molecular Biology (7.3k citations) and Immunology (2.2k citations). Douglas V. Faller has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Nancy C. Andrews, Susan P. Perrine, Stella Kourembanas, Steven J. Mentzer, Cyrus Vaziri, Lora W. Forman, Philip A. Marsden, Gerald V. Denis, Robert L. Hannan and Nancy Hopkins. Their work appears in journals such as Blood, Journal of Biological Chemistry, Journal of Virology, Journal of Cellular Physiology and Molecular and Cellular Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact